VIVIMUSTA

Peak

bendamustine hydrochloride

NDAINTRAVENOUSSOLUTION
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9

Clinical Trials (5)

NCT01739491N/AWithdrawn

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

Started Oct 2014
0
Chronic Lymphocytic Leukemia
NCT02240719Phase 1Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Started Oct 2014
20 enrolled
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular Lymphoma+5 more
NCT01900509Phase 1Completed

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Started Aug 2013
16 enrolled
Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia
NCT01429025Phase 1Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Started May 2012
26 enrolled
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
NCT04569838Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Started May 2012

Loss of Exclusivity

LOE Date
Jul 29, 2042
199 months away
Patent Expiry
Jul 29, 2042

Patent Records (4)

Patent #ExpiryTypeUse Code
11707450
Jul 29, 2042
Product
11844784
Jul 29, 2042
Product
12208086
Jul 29, 2042
Product
12419867
Jul 29, 2042
Product